Skip to main content
An official website of the United States government

Biometry

Contributes to the rigor and reproducibility of cancer research through statistical consultation and mathematical modeling. Supports research in biostatistical methods and data analytics, machine learning, and artificial intelligence for cancer risk prediction and reduction.

On This Page

  • All Heading 2s will automatically be pulled in to this list.
  • Do not edit the content on this template.

Resources

Staff List

Photo Name, Email, Phone Room Group(s)/Office
Berger, Vance, Ph.D.
vance.berger@nih.gov
240-276-7142
5E628 Statistician | Biometry
Bowles, Heather, Ph.D.
heather.bowles@nih.gov
240-276-6794
5E640 Program Officer | Biometry
Cancer Prevention Fellowship Program
Dodd, Kevin, Ph.D.
kevin_dodd@nih.gov
240-276-7021
5E126 Deputy Chief | Biometry
Hu, Ping, Sc.D.
ping.hu@nih.gov
240-276-7015
5E118 Statistician | Biometry
Morris, Lawrence
lawrence.morris@nih.gov
240-276-7137
5E112 Program Specialist | Biometry
Prorok, Philip C, Ph.D. [C]
philip.prorok@nih.gov
240-276-7131
Contractor | Office of the Director
Biometry
Sirota, Lev, Ph.D. [C]
lev.sirota@nih.gov
240-276-5127
5E114 Contractor | Biometry
Uzzell, Norwood
norwood.uzzell@nih.gov
240-276-7141
5E222 Program Support Assistant | Biometry
Xu, Jian-Lun, Ph.D.
jian-lun.xu@nih.gov
240-276-7023
5E128 Statistician | Biometry

Grants

PI Name Sort descending PI Organization Title Grant Number Program Official
Shirwan, Haval

University Of Missouri-Columbia
United States

Developing a novel agonist of CD137 for cancer immunoprevention 5UG3CA290305-02 Altaf Mohammed, Ph.D.
Shu, Xiao-Ou

Vanderbilt University Medical Center
United States

Use of Circulating MicroRNAs for Early Detection and Risk Assessment for Pancreatic Cancer 5R01CA227133-05 Matthew Young, Ph.D.
Shureiqi, Imad

University Of Michigan At Ann Arbor
United States

ALOX15 regulation of colon cancer invasiveness via PI3P-linoleic acid metabolism 5R01CA266223-04 Nancy J. Emenaker, Ph.D., RDN, LD, FAND
Siddique, Shahzad

Commonspirit Health Research Institute
United States

CIRI Oncology Research Alliance 3UG1CA189809-11S1 Vanessa A. White, M.P.H.
Sidransky, David

Johns Hopkins University
United States

Racial differences in Immunogenetic Tumorigenesis of Head and Neck Squamous Cell Carcinoma 5R01CA265975-04 Wendy Wang, Ph.D., M.Sc.
Sieren, Jessica C

University Of Iowa
United States

Lung cancer screening efficacy enhanced through radiomic and epigenetic biomarkers 5R01CA267820-03 Nicholas Hodges, Ph.D.
Sigel, Keith Magnus

Icahn School Of Medicine At Mount Sinai
United States

The effectiveness of screening women with lower genital tract neoplasia or cancers for anal cancer precursors 4R01CA256660-05 Vikrant Sahasrabuddhe, M.B.B.S., M.P.H., Dr.P.H.
Simeone, Diane M

University Of California, San Diego
United States

Biomarker Validation in Pancreatic Cystic Neoplasms 5U01CA282272-03 Matthew Young, Ph.D.
Siminski, Suzanne M.

Frontier Sci & Technology Rsch Fdn, Inc
United States

CASCADE Coordinating Center 5U24CA275417-04 Maria Silvina Frech, Ph.D., M.S.
Singal, Amit

Ut Southwestern Medical Center
United States

Precision Risk Stratification and Screening for HCC among Patients with Indeterminate Liver Nodules 4U01CA283935-03 Sidney Fu, M.D.
Singal, Amit

Ut Southwestern Medical Center
United States

Precision Screening for Hepatocellular Carcinoma in Patients with Cirrhosis 5R01CA222900-06
Singal, Amit

Ut Southwestern Medical Center
United States

Clinical Validation Center for Hepatocellular Carcinoma 5U01CA271887-04 Indu Kohaar, Ph.D., M.Phil., M.Sc.
Singal, Amit

Ut Southwestern Medical Center
United States

Precision Risk Stratification and Screening for HCC among Patients with Cirrhosis in the United States 5U01CA230694-05
Siskind, Leah J

University Of Louisville
United States

Protecting the kidney from cisplatin induced injury and progression to chronic kidney disease 1R01CA305985-01 Marjorie Perloff, M.D.
Skates, Steven J

Massachusetts General Hospital
United States

Proteomic Analyses of Serial Prediagnostic PLCO Serum in Cases and Controls to Identify Early Detection Ovarian Cancer Biomarkers Rising in a Substantial Fraction of Cases and Stable in Most Controls 5U01CA260758-05 Claire Zhu, Ph.D.